Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
Tweet Send to a Friend
Goldman Sachs analyst Andrea Tan reiterated a Buy rating and $571.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
